s_150324_4a
EPN · Posterior Fossa EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Posterior Fossa EPN
- cancer_type
- EPN
- subtype
- Posterior Fossa EPN
- e1_e2
- E2
- umap1_2d
- -6.111005403
- umap2_2d
- 0.548465498
- umap1_3d
- 0.742646966
- umap2_3d
- 3.769144933
- umap3_3d
- -0.016818297
- dataset
- EPN-Heidelberg
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.450
- E2F_TARGETS+0.420
- CHOLESTEROL_HOMEOSTASIS+0.390
- NOTCH_SIGNALING+0.360
- OXIDATIVE_PHOSPHORYLATION+0.350
- MITOTIC_SPINDLE+0.280
- MYC_TARGETS_V1+0.270
- WNT_BETA_CATENIN_SIGNALING+0.260
- FATTY_ACID_METABOLISM+0.240
- MYC_TARGETS_V2+0.240
Top 10 suppressed
- TNFA_SIGNALING_VIA_NFKB-0.560
- INTERFERON_ALPHA_RESPONSE-0.540
- INTERFERON_GAMMA_RESPONSE-0.540
- ALLOGRAFT_REJECTION-0.480
- IL6_JAK_STAT3_SIGNALING-0.440
- INFLAMMATORY_RESPONSE-0.390
- P53_PATHWAY-0.370
- APOPTOSIS-0.330
- COMPLEMENT-0.330
- HYPOXIA-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR5088851 | — | — | 0.864 |
| 2 | MNG164 | — | — | 0.858 |
| 3 | BS_KDSTG5YY | EPN | Posterior Fossa EPN | 0.854 |
| 4 | BS_KDSTG5YY | Posterior Fossa Ependymoma | — | 0.847 |
| 5 | X97abcebb.f885.4eca.9af4.91a0adb97578 | — | cohortMD1 | 0.844 |
| 6 | TCGA-58-8392-01A-11R-2326-07 | — | cohortSQ2 | 0.843 |
| 7 | SRR8613736 | — | E | 0.836 |
| 8 | SRR35579839 | — | B | 0.833 |
| 9 | BS_53M8PP88 | EPN | EPN Tumor | 0.831 |
| 10 | TCGA-77-8154-01A-11R-2247-07 | — | cohortSQ1 | 0.819 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.450 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.420 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.390 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.360 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.350 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.280 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.270 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.260 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.240 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.240 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.180 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.160 | Temsirolimus | — uncovered |
| SPERMATOGENESIS | 0.150 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.140 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.130 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.110 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.060 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.060 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.060 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.040 | Inavolisib | — uncovered |